CD8A and neoplasm: Up to now, as antigen transportation platform for tumor-associated antigens (TAAs) and/or immune adjuvants, MOFs were increasingly used for tumor treatment, where TAAs were delivered to antigen-presenting cells (APCs) to induce CD8+ cytotoxic T lymphocyte responses, and adjuvants were used to amplify this response.